Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.
Stock Information for Capricor Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.